HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

House Energy And Commerce Lists Infant Formula Crisis First In Stating FDA Oversight Priorities

Executive Summary

Infant formula supply shortage affecting US since early 2022 is first among multiple FDA concerns Energy and Commerce GOP leadership stated in plan submitted to Oversight and Rules Committee, as required in a standing House rule.

You may also be interested in...



FDA Report On US Formula Supply Doesn’t Stop Criticism From Congress, Former Food Policy Chief

On same day agency published strategy for ensuring formula supply, House Oversight Committee subcommittee members made clear they’re not convinced FDA could prevent repeat of 2022 shortage. Recently resigned FDA food policy chief also has doubts.

US Supplement Industry Left Waiting For Changes In FDA ‘Unified’ Food Programs Reorganization

“Something needed to be done” to improve FDA’s regulation of human foods supply, says Commissioner Califf says. “Dietary supplements is a whole different kettle of fish that we can discuss at a later time.”

In Food Programs Restructuring, US FDA Has Designs On Clear Priorities, Chain Of Command

Following reviews prompted largely by formula supply crisis, FDA will move Center for Food Safety and Applied Nutrition and commissioner’s Office of Food Programs and Response to Human Foods Program headed by deputy commissioner. Office of Regulatory Affairs' structure also changing “to support the FDA organization as a whole,” says Commissioner Califf.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel